Latest Atossa Genetics Inc (ATOS) Headlines Per
Post# of 94
Posted On: 03/13/2014 5:35:18 AM
Latest Atossa Genetics Inc (ATOS) Headlines
Personalized Medicine and Companion Diagnostic Market Discussed in New Report by Kelly Scientific Publications Available at MarketPublishers.com
PRWeb - Fri Mar 07, 12:03PM CST
During the last 20 years, the ongoing genetic advances have considerably facilitated the emergence of personalized medicine sector as an important player in the overall healthcare universe. Human genome sequencing has propelled the pharmacogenetics sector. Furthermore, personalized medicine also takes into account pharmacogenomics studies, where protein and genetic interactions yield the potential drug targets. The key objective of personalized medicine is to offer individualized care that is more effective and specific to the potential patients. Targeted and personalized medicine R&D efforts are aimed at increasing the efficiency of the therapeutic area via genetic testing along with companion diagnostics. The introduction of novel personalized medicine will likely reduce the frequency of adverse drug reactions and thus have a significant influence on health economics. Diagnostic and developmental companies are predicted to take benefit from lower discovery and commercialization costs, as well as from more specific market sub-types awaited in the years ahead.
Personalized Medicine and Companion Diagnostic Market - 2014 Gives Details of their Operations, Products, Financials and Business Strategy
M2 - Thu Mar 06, 9:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/rpc89x/personalized) has announced the addition of the "Personalized Medicine and Companion Diagnostic Market - A Strategic Analysis of Industry Trends, Technologies, Participants and Environment" report to their offering. This is a comprehensive account of the market size, segmentation, key players, SWOT analysis, influential technologies, and business and economic environments. The report is supported by 263 tables & figures over 224 pages. The personalized medicine (global) market is presented as follows: -By Company -By Geography -By Segment -By Sub-market A wealth of financial data & business strategy information is provided including: -Up-to-date company financials, sales & revenue figures -Business Model Strategies for Diagnostic, Pharmaceutical and Biotechnology Companies -Business Model Strategies for Providers. Provider Systems and Academic Medical Centres -Business Model Strategies for Payers & Governments -Private and Public Funding and Personalized Medicine Reimbursement -Revisions to Current Payment Systems and intellectual property -How to Gain Market Penetration in the EU -Cost-effectiveness and Business Value of Personalized Medicine -Consumer genomics and POC market -Therapeutics and Companion Diagnostics (e.g., BRAC Analysis, Oncotype Dx , KRAS Mutations) -Comprehensive account of company product portfolios & kits This report highlights a number of significant Indian pharmacos and gives details of their operations, products, financials and business strategy. -23andMe -Affymetrix -Astex Pharmaceuticals -Atossa Genetics -CuraGen -Celera Corporation (Quest Diagnostics) -Celldex Therapeutics -deCode Genetics (Amgen) -Illumina -Genelex -Myriad -Nodality -Qiagen This report tackles key concerns to the personalized medicine market such as: -Lack of regulatory policy and legislation in the US and Europe -Reimbursement schemes and payers concerns -Transition of investigational diagnostic assays and therapeutics to clinical practice -Direct to consumer (DTC) test kits and implications for the public This detailed report is supported with 263 figures and tables over 224 pages and profiles the main pharmacos in personalized medicine. For more information visit http://www.researchandmarkets.com/research/rp...rsonalized About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Atossa Genetics to submit additional information to the US FDA for ForeCYTE Breast Aspirator
M2 - Wed Mar 05, 6:15AM CST
Breast health company Atossa Genetics (NASDAQ:ATOS) disclosed on Tuesday that the US Food and Drug Administration (FDA) has requested additional information related to the company's 510(k) application for the clearance of its ForeCYTE Breast Aspirator.
Atossa Genetics Inc. Announces FDA Response to 510(k) Submission for ForeCYTE Breast Aspirator
Marketwire - Tue Mar 04, 7:30AM CST
Atossa Genetics Inc. (NASDAQ: ATOS) announced today that it has received a request for additional information from the U.S. Food and Drug Administration (FDA) related to its 510(k) application for the ForeCYTE Breast Aspirator. Atossa plans to request an extension to the 30 day time limit by which a response must be provided to the FDA. If the request for an extension is granted, Atossa will have up to 180 days to provide a response to the FDA's questions. Atossa does not view the FDA's request for additional information as unusual or unexpected and will continue to work toward final clearance of the submission.
Atossa Genetics elects Richard I. Steinhart to board
M2 - Tue Mar 04, 5:10AM CST
Breast health company Atossa Genetics (NASDAQ:ATOS) revealed on Monday the addition of Richard I. Steinhart to its board of directors
Richard I. Steinhart Joins Atossa Genetics' Board of Directors
Marketwire - Mon Mar 03, 11:30AM CST
Atossa Genetics Inc. (NASDAQ: ATOS), announced today that Richard I. Steinhart has joined the Company's Board of Directors and has been appointed a Member of the Audit Committee and Compensation Committee.
3 Stocks Under $10 Making Big Moves
at The Street - Wed Feb 26, 5:00AM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
BMO Economics: Business Investment and Housing to Lift Illinois' Economy 2.5 Percent in 2014
Marketwire - Tue Feb 04, 7:01AM CST
While economic growth in Illinois was challenged last year by a softening in factory activity and exports, 2014 will see the economy improve at a 2.5 percent pace, according to the bi-annual U.S. State Monitor Report from BMO Economics.
Shareholder Rights Law Firm Johnson & Weaver, LLP Announces Investigation of Certain Officers and Directors of Atossa Genetics, Inc.
Business Wire - Fri Jan 31, 10:31AM CST
Shareholder Rights Law Firm Johnson & Weaver, LLP today announced that it is investigating whether the board of directors of Atossa Genetics, Inc. (NASDAQ:ATOS) breached its fiduciary duties to shareholders related to Atossa's October 4, 2013 disclosure that it would be forced to recall its ForeCYTE Breast Health Test and Mammary Aspiration Specimen Cytology Test. The recall was necessary to address concerns raised by the U.S. Food and Drug Administration ("FDA"). The FDA previously alerted the Company to concerns regarding the recalled products back in February 2013, and those concerns may not have been addressed by Atossa.
Atossa Genetics Inc completes public offering of 5.834m units
M2 - Thu Jan 30, 3:30AM CST
Breast health company Atossa Genetics Inc (NASDAQ:ATOS) reported on Wednesday the completion of its public offering of 5,834,234 units.
Atossa Genetics Inc. Announces Closing of a Public Offering of Common Stock and Warrants
Marketwire - Wed Jan 29, 4:00PM CST
Atossa Genetics Inc. (NASDAQ: ATOS) today announced that it has closed a public offering of 5,834,234 units at a price to the public of $2.40 per unit. The Company has received approximately $14.0 million in gross proceeds. Each unit consists of one share of common stock and one warrant to purchase 0.20 of a share of common stock.
Real Good Solar Takes On New Name, Ticker Symbol and Strategy: Real Goods Solar Inc. (NASDAQ:RSOL), Atossa Genetics Inc. (NASDAQ: ATOS), Chelsea Therapeutics International, Ltd. (NASDAQ:CHTP)
ACCESSWIRE - Tue Jan 28, 7:02AM CST
What makes a pioneering solar energy company change its name, ticker symbol and strategy after 36 years?
Atossa Genetics prices public offering at USD2.40 per unit
M2 - Mon Jan 27, 6:18AM CST
US-based breast health company Atossa Genetics Inc (NASDAQ:ATOS) said on Friday that it has priced its public offering of approximately 5.8m units.
Atossa Genetics Inc. Announces Pricing of a Public Offering of Common Stock and Warrants
Marketwire - Fri Jan 24, 7:30AM CST
Atossa Genetics Inc. (NASDAQ: ATOS) today announced that it has priced a public offering of approximately 5.8 million units at a price to the public of $2.40 per unit. The Company has received commitments and indications for approximately $14.0 million in gross proceeds. The sale of the units is expected to close on or about January 29, 2014, subject to the satisfaction of customary closing conditions. Each unit consists of one share of common stock and one warrant to purchase 0.20 of a share of common stock.
Atossa Genetics Inc proposes public offering of units
M2 - Fri Jan 24, 4:54AM CST
Breast health company Atossa Genetics Inc (NASDAQ:ATOS) said on Thursday that it plans to offer units consisting of shares of common stock and warrants in a public offering.
Atossa Genetics Inc. Announces Proposed Public Offering of Common Stock and Warrants
Marketwire - Thu Jan 23, 3:15PM CST
Atossa Genetics Inc. (NASDAQ: ATOS) today announced that it intends to offer units consisting of shares of common stock and warrants in a public offering. While the offering is expected to price before 9:30 am EST on January 24, 2014, the offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Dawson James Securities, Inc. will serve as the sole book-running manager for the offering.
3 Stocks Under $10 in Breakout Territory
at The Street - Wed Jan 22, 6:00AM CST
These under-$10 stocks are within range of triggering major breakout trades.
Steel Pipe & Tube Manufacturers in China - Analysis of The Top 90 Companies
M2 - Wed Jan 15, 8:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/r9cplw/steel_pipe_and) has announced the addition of the "Steel Pipe & Tube Manufacturers (China)" report to their offering. This report provides a detailed overview of China's Steel Pipe and Tube Manufacturers market and delivers a comprehensive individual analysis on the top 90 companies. It includes a wealth of information on the financial trends over the past four years. A quick glance of this report will tell you that 8 companies have a declining Plimsoll financial rating, while 42 have shown good sales growth. Each of the largest 90 companies is meticulously scrutinised in a one-page individual assessment and is analysed using the most up-to-date and current financial data. Every business is examined on the following features: - The Plimsoll Chart: A graphical assessment of a company's financial performance - Four year assessment of the profit/loss and balance sheet - A written summary highlighting key performance issues Subsequently, you will receive a thorough market analysis highlighting the latest changes in the Chinese Steel Pipe and Tube Manufacturers market. This section includes: - Best Trading Partners - Sales Growth Analysis - Profit Analysis - Market Size - Rankings Reasons To Buy - See the market leaders - Identify companies heading for failure - Seek out the most attractive acquisition - Analyse industry trends - Benchmark their own financial performance For more information visit http://www.researchandmarkets.com/research/r9...l_pipe_and About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
10-Q: GLOBE NET WIRELESS CORP.
Edgar Online - Tue Jan 14, 12:32PM CST
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION
Atossa Genetics to Present at Two Upcoming Investor Conferences
Marketwire - Thu Jan 09, 3:01PM CST
Atossa Genetics, Inc. (NASDAQ: ATOS), the Breast Health Company(TM), today announced that management will present at two upcoming investor conferences: Sidoti Semi-Annual Microcap Conference on Monday, January 13, 2014, at 10:00 a.m. Eastern Time, at the Grand Hyatt Hotel in New York City, and Biotech Showcase on Wednesday, January 15, 2014, at 3:00 p.m. Pacific Time, at the Parc 55 Wyndham San Francisco - Union Square in San Francisco, California.
Personalized Medicine and Companion Diagnostic Market Discussed in New Report by Kelly Scientific Publications Available at MarketPublishers.com
PRWeb - Fri Mar 07, 12:03PM CST
During the last 20 years, the ongoing genetic advances have considerably facilitated the emergence of personalized medicine sector as an important player in the overall healthcare universe. Human genome sequencing has propelled the pharmacogenetics sector. Furthermore, personalized medicine also takes into account pharmacogenomics studies, where protein and genetic interactions yield the potential drug targets. The key objective of personalized medicine is to offer individualized care that is more effective and specific to the potential patients. Targeted and personalized medicine R&D efforts are aimed at increasing the efficiency of the therapeutic area via genetic testing along with companion diagnostics. The introduction of novel personalized medicine will likely reduce the frequency of adverse drug reactions and thus have a significant influence on health economics. Diagnostic and developmental companies are predicted to take benefit from lower discovery and commercialization costs, as well as from more specific market sub-types awaited in the years ahead.
Personalized Medicine and Companion Diagnostic Market - 2014 Gives Details of their Operations, Products, Financials and Business Strategy
M2 - Thu Mar 06, 9:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/rpc89x/personalized) has announced the addition of the "Personalized Medicine and Companion Diagnostic Market - A Strategic Analysis of Industry Trends, Technologies, Participants and Environment" report to their offering. This is a comprehensive account of the market size, segmentation, key players, SWOT analysis, influential technologies, and business and economic environments. The report is supported by 263 tables & figures over 224 pages. The personalized medicine (global) market is presented as follows: -By Company -By Geography -By Segment -By Sub-market A wealth of financial data & business strategy information is provided including: -Up-to-date company financials, sales & revenue figures -Business Model Strategies for Diagnostic, Pharmaceutical and Biotechnology Companies -Business Model Strategies for Providers. Provider Systems and Academic Medical Centres -Business Model Strategies for Payers & Governments -Private and Public Funding and Personalized Medicine Reimbursement -Revisions to Current Payment Systems and intellectual property -How to Gain Market Penetration in the EU -Cost-effectiveness and Business Value of Personalized Medicine -Consumer genomics and POC market -Therapeutics and Companion Diagnostics (e.g., BRAC Analysis, Oncotype Dx , KRAS Mutations) -Comprehensive account of company product portfolios & kits This report highlights a number of significant Indian pharmacos and gives details of their operations, products, financials and business strategy. -23andMe -Affymetrix -Astex Pharmaceuticals -Atossa Genetics -CuraGen -Celera Corporation (Quest Diagnostics) -Celldex Therapeutics -deCode Genetics (Amgen) -Illumina -Genelex -Myriad -Nodality -Qiagen This report tackles key concerns to the personalized medicine market such as: -Lack of regulatory policy and legislation in the US and Europe -Reimbursement schemes and payers concerns -Transition of investigational diagnostic assays and therapeutics to clinical practice -Direct to consumer (DTC) test kits and implications for the public This detailed report is supported with 263 figures and tables over 224 pages and profiles the main pharmacos in personalized medicine. For more information visit http://www.researchandmarkets.com/research/rp...rsonalized About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Atossa Genetics to submit additional information to the US FDA for ForeCYTE Breast Aspirator
M2 - Wed Mar 05, 6:15AM CST
Breast health company Atossa Genetics (NASDAQ:ATOS) disclosed on Tuesday that the US Food and Drug Administration (FDA) has requested additional information related to the company's 510(k) application for the clearance of its ForeCYTE Breast Aspirator.
Atossa Genetics Inc. Announces FDA Response to 510(k) Submission for ForeCYTE Breast Aspirator
Marketwire - Tue Mar 04, 7:30AM CST
Atossa Genetics Inc. (NASDAQ: ATOS) announced today that it has received a request for additional information from the U.S. Food and Drug Administration (FDA) related to its 510(k) application for the ForeCYTE Breast Aspirator. Atossa plans to request an extension to the 30 day time limit by which a response must be provided to the FDA. If the request for an extension is granted, Atossa will have up to 180 days to provide a response to the FDA's questions. Atossa does not view the FDA's request for additional information as unusual or unexpected and will continue to work toward final clearance of the submission.
Atossa Genetics elects Richard I. Steinhart to board
M2 - Tue Mar 04, 5:10AM CST
Breast health company Atossa Genetics (NASDAQ:ATOS) revealed on Monday the addition of Richard I. Steinhart to its board of directors
Richard I. Steinhart Joins Atossa Genetics' Board of Directors
Marketwire - Mon Mar 03, 11:30AM CST
Atossa Genetics Inc. (NASDAQ: ATOS), announced today that Richard I. Steinhart has joined the Company's Board of Directors and has been appointed a Member of the Audit Committee and Compensation Committee.
3 Stocks Under $10 Making Big Moves
at The Street - Wed Feb 26, 5:00AM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
BMO Economics: Business Investment and Housing to Lift Illinois' Economy 2.5 Percent in 2014
Marketwire - Tue Feb 04, 7:01AM CST
While economic growth in Illinois was challenged last year by a softening in factory activity and exports, 2014 will see the economy improve at a 2.5 percent pace, according to the bi-annual U.S. State Monitor Report from BMO Economics.
Shareholder Rights Law Firm Johnson & Weaver, LLP Announces Investigation of Certain Officers and Directors of Atossa Genetics, Inc.
Business Wire - Fri Jan 31, 10:31AM CST
Shareholder Rights Law Firm Johnson & Weaver, LLP today announced that it is investigating whether the board of directors of Atossa Genetics, Inc. (NASDAQ:ATOS) breached its fiduciary duties to shareholders related to Atossa's October 4, 2013 disclosure that it would be forced to recall its ForeCYTE Breast Health Test and Mammary Aspiration Specimen Cytology Test. The recall was necessary to address concerns raised by the U.S. Food and Drug Administration ("FDA"). The FDA previously alerted the Company to concerns regarding the recalled products back in February 2013, and those concerns may not have been addressed by Atossa.
Atossa Genetics Inc completes public offering of 5.834m units
M2 - Thu Jan 30, 3:30AM CST
Breast health company Atossa Genetics Inc (NASDAQ:ATOS) reported on Wednesday the completion of its public offering of 5,834,234 units.
Atossa Genetics Inc. Announces Closing of a Public Offering of Common Stock and Warrants
Marketwire - Wed Jan 29, 4:00PM CST
Atossa Genetics Inc. (NASDAQ: ATOS) today announced that it has closed a public offering of 5,834,234 units at a price to the public of $2.40 per unit. The Company has received approximately $14.0 million in gross proceeds. Each unit consists of one share of common stock and one warrant to purchase 0.20 of a share of common stock.
Real Good Solar Takes On New Name, Ticker Symbol and Strategy: Real Goods Solar Inc. (NASDAQ:RSOL), Atossa Genetics Inc. (NASDAQ: ATOS), Chelsea Therapeutics International, Ltd. (NASDAQ:CHTP)
ACCESSWIRE - Tue Jan 28, 7:02AM CST
What makes a pioneering solar energy company change its name, ticker symbol and strategy after 36 years?
Atossa Genetics prices public offering at USD2.40 per unit
M2 - Mon Jan 27, 6:18AM CST
US-based breast health company Atossa Genetics Inc (NASDAQ:ATOS) said on Friday that it has priced its public offering of approximately 5.8m units.
Atossa Genetics Inc. Announces Pricing of a Public Offering of Common Stock and Warrants
Marketwire - Fri Jan 24, 7:30AM CST
Atossa Genetics Inc. (NASDAQ: ATOS) today announced that it has priced a public offering of approximately 5.8 million units at a price to the public of $2.40 per unit. The Company has received commitments and indications for approximately $14.0 million in gross proceeds. The sale of the units is expected to close on or about January 29, 2014, subject to the satisfaction of customary closing conditions. Each unit consists of one share of common stock and one warrant to purchase 0.20 of a share of common stock.
Atossa Genetics Inc proposes public offering of units
M2 - Fri Jan 24, 4:54AM CST
Breast health company Atossa Genetics Inc (NASDAQ:ATOS) said on Thursday that it plans to offer units consisting of shares of common stock and warrants in a public offering.
Atossa Genetics Inc. Announces Proposed Public Offering of Common Stock and Warrants
Marketwire - Thu Jan 23, 3:15PM CST
Atossa Genetics Inc. (NASDAQ: ATOS) today announced that it intends to offer units consisting of shares of common stock and warrants in a public offering. While the offering is expected to price before 9:30 am EST on January 24, 2014, the offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Dawson James Securities, Inc. will serve as the sole book-running manager for the offering.
3 Stocks Under $10 in Breakout Territory
at The Street - Wed Jan 22, 6:00AM CST
These under-$10 stocks are within range of triggering major breakout trades.
Steel Pipe & Tube Manufacturers in China - Analysis of The Top 90 Companies
M2 - Wed Jan 15, 8:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/r9cplw/steel_pipe_and) has announced the addition of the "Steel Pipe & Tube Manufacturers (China)" report to their offering. This report provides a detailed overview of China's Steel Pipe and Tube Manufacturers market and delivers a comprehensive individual analysis on the top 90 companies. It includes a wealth of information on the financial trends over the past four years. A quick glance of this report will tell you that 8 companies have a declining Plimsoll financial rating, while 42 have shown good sales growth. Each of the largest 90 companies is meticulously scrutinised in a one-page individual assessment and is analysed using the most up-to-date and current financial data. Every business is examined on the following features: - The Plimsoll Chart: A graphical assessment of a company's financial performance - Four year assessment of the profit/loss and balance sheet - A written summary highlighting key performance issues Subsequently, you will receive a thorough market analysis highlighting the latest changes in the Chinese Steel Pipe and Tube Manufacturers market. This section includes: - Best Trading Partners - Sales Growth Analysis - Profit Analysis - Market Size - Rankings Reasons To Buy - See the market leaders - Identify companies heading for failure - Seek out the most attractive acquisition - Analyse industry trends - Benchmark their own financial performance For more information visit http://www.researchandmarkets.com/research/r9...l_pipe_and About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
10-Q: GLOBE NET WIRELESS CORP.
Edgar Online - Tue Jan 14, 12:32PM CST
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION
Atossa Genetics to Present at Two Upcoming Investor Conferences
Marketwire - Thu Jan 09, 3:01PM CST
Atossa Genetics, Inc. (NASDAQ: ATOS), the Breast Health Company(TM), today announced that management will present at two upcoming investor conferences: Sidoti Semi-Annual Microcap Conference on Monday, January 13, 2014, at 10:00 a.m. Eastern Time, at the Grand Hyatt Hotel in New York City, and Biotech Showcase on Wednesday, January 15, 2014, at 3:00 p.m. Pacific Time, at the Parc 55 Wyndham San Francisco - Union Square in San Francisco, California.
(0)
(0)Atossa Genetics, Inc. (ATOS) Stock Research Links
Scroll down for more posts ▼